The first provincial-level cross-regional procurement alliance for Chinese patent medicine is coming!

Medical Network, August 18,recently, a provincial medical insurance bureau's "Letter on Inviting Participating in the Centralized Procurement of Proprietary Chinese Patent Medicine Provincial Cross-regional Alliance" has been circulating in the industry
.
The attachment also contains a "Catalog of Procurement Varieties of Proprietary Traditional Chinese Medicines".
After sorting out, it is found that there are a total of 17 product groups, involving more than 70 varieties
.
Some large varieties of traditional Chinese medicine are listed, including Xuesaitong injection, Xueshuantong injection, Jinshuibao tablets, Shenmai injection, Shengmai injection and so on
.

 

Under the trend of the country to explore mass procurement of Chinese patent medicines, if the group is successful, this will be the first procurement alliance that specifically targets Chinese patent medicines.
However, how many provinces and cities will join, how to formulate the procurement plan, and whether the procurement varieties will be Any adjustments require further follow-up and attention
.
According to the initial procurement catalogue, in addition to covering some large varieties, with a large number of purchased varieties, and mainly oral medicines, as to how to purchase Chinese patent medicines, the varieties are also grouped according to the same group.
This grouping mode or Make the varieties in the group PK
.

 

Chinese medicine into the Central Purchasing large variety of sales further pressure

 

In recent years, affected by the adjustment of medical insurance policies and the gradual refinement of the rational drug use policy in hospitals , the overall growth rate of the Chinese patent medicine market has continued to slow down
.
According to data from Mi Nei.
com, in 2019, China's public medical institutions' terminal sales of proprietary Chinese medicines were 283 billion yuan, a negative growth of 1.
7% for the first time
.
Among them, affected by policies such as medical insurance restrictions, key monitoring, and revision of instructions, the overall market for Chinese medicine injections has declined
.

 

High-priced and large-volume varieties have also become the focus of mass procurement of proprietary Chinese medicines
.
For example, Xuesaitong and Xueshuantong have appeared in this alliance procurement list, and Qinghai Province has tested the water before
.
In 2018 China's public medical institutions' terminal TCM injection sales rankings, the sales of Xueshuantong for injection (lyophilized) and Xuesaitong for injection (lyophilized) both exceeded 5 billion yuan, ranking first and second respectively on the TOP list
.
In 2019, the sales of Xueshuantong for injection (lyophilized) reached 6.
283 billion yuan, and Xuesaitong for injection (lyophilized) fell to 3.
928 billion yuan
.

 

　　In addition, Shenmai injection and Shengmai injection have also attracted market attention due to their recommendation in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Seventh Edition)"
.
In the terminal market of China's public medical institutions in 2018, the annual sales of these two varieties exceeded 1 billion yuan, and Shenmai injection exceeded 3 billion yuan
.
However, sales of both varieties declined in 2019, with Shenmai injection sales of 2.
673 billion yuan and Shengmai injection sales of 973 million yuan
.

 

　　While the TCM injection market has declined, some TCM oral medicine markets have performed well
.
In 2020, Jinshuibao film will grow against the trend
.
According to data from Mi Nei.
com, Jinshuibao tablets are the exclusive product of Jiangxi Jimin Trusted Pharmaceutical
.
In recent years, the sales of Jinshuibao tablets in public hospitals in key cities have grown rapidly, from less than 50 million yuan in 2017 to nearly 400 million yuan in 2019
.

 

　　Or from local exploration to national spread

 

　　The national level has repeatedly stated that it will include proprietary Chinese medicines in centralized procurement
.
A few days ago, the National Medical Insurance Administration made it clear in its response to the recommendation No.
4126 of the Fourth Session of the 13th National People’s Congress: The next step will be to work with relevant departments to improve the quality evaluation standards of proprietary Chinese medicines and formula granules, and insist on quality first, and based on clinical needs.
As a guide, starting with high-priced and large-volume varieties, scientifically and steadily promote the reform of centralized procurement of proprietary Chinese medicines and formula granules
.

 

　　Previously, Qinghai Province, Zhejiang Jinhua, Puyang, Henan and other places have a large demand for the part, to the high amount of drugs carried out to explore the kinds of Jicai, achieved positive results
.
The first batch of drug purchase lists issued by Qinghai Province includes Xuesaitong, Xueshuantong, Danshen polyphenolate for injection, Tanreqing, and Xiyanping traditional Chinese medicine injections
.
The second batch of drug purchases carried out by Jinhua City, Zhejiang Province, involving 274 varieties and a total of 180 Chinese patent medicines, including Pudilan Anti-inflammatory Oral Liquid, Yunnan Baiyao Aerosol and Capsules, Shenmai Injection, Xiao'er Soy Bean Granules, etc.

.
Finally, selected product 93, accounting for over 40% of the type of medicine, medicine is 39, including injection, Danshen tablets, pills Liuweidihuang, Qingkailing particles
.

 

　　Since the beginning of this year, procurement of Chinese patent medicines has also been accelerated
.
In April this year, Guangdong took the lead in the centralized procurement of drugs from the 16-province alliance involving dozens of proprietary Chinese medicines
.
Recently, the Sichuan Provincial Bureau issued health care "health care support Sichuan Province medicine development a number of policy" clearly to the provincial inter-provincial or regional alliances, based on the amount of purchases carried out with medicine, Chinese medicine to promote the production companies of high-quality development
.

 

　　Regarding the issue of the inclusion of Chinese patent medicines in centralized procurement, the National Medical Insurance Bureau has stated that it will guide and promote local governments to conduct research on centralized procurement of Chinese patent medicines and other medicines
.
Some people in the industry believe that local special pilot projects may be initiated in 2021, and the country will further develop centralized procurement of proprietary Chinese medicines on this basis when the time is ripe
.

 

　　From the perspective of the industry, although proprietary Chinese medicines have their particularities compared with chemical medicines, especially for the exclusive varieties of Chinese medicines, because there is no competition, there is a lack of motivation to reduce prices
.
In this regard, the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Drug Centralized and Volume Procurement" clearly proposes to explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized and volumetric procurement
.
This also provides a basic follow for the centralized procurement of Chinese patent medicines
.

 

　　The industry believes that the fully competitive or large-volume varieties may be the first to be included, and the market of Chinese patent medicines with a scale of over 300 billion yuan will officially enter the "shuffle" stage with volume purchases
.

 

　　Catalog of varieties of Chinese patent medicines that are purchased in a centralized manner

　　Medical Network, August 18, 　recently, a provincial medical insurance bureau's "Letter on Inviting Participating in the Centralized Procurement of Proprietary Chinese Patent Medicine Provincial Cross-regional Alliance" has been circulating in the industry
.
The attachment also contains a "Catalog of Procurement Varieties of Proprietary Traditional Chinese Medicines".
After sorting out, it is found that there are a total of 17 product groups, involving more than 70 varieties
.
Some large varieties of traditional Chinese medicine are listed, including Xuesaitong injection, Xueshuantong injection, Jinshuibao tablets, Shenmai injection, Shengmai injection and so on
.

 

　　Under the trend of the country to explore mass procurement of Chinese patent medicines, if the group is successful, this will be the first procurement alliance that specifically targets Chinese patent medicines.
However, how many provinces and cities will join, how to formulate the procurement plan, and whether the procurement varieties will be Any adjustments require further follow-up and attention
.
According to the initial procurement catalogue, in addition to covering some large varieties, with a large number of purchased varieties, and mainly oral medicines, as to how to purchase Chinese patent medicines, the varieties are also grouped according to the same group.
This grouping mode or Make the varieties in the group PK
.

 

　　Chinese medicine into the Central Purchasing large variety of sales further pressure

 

　　In recent years, affected by the adjustment of medical insurance policies and the gradual refinement of the rational drug use policy in hospitals , the overall growth rate of the Chinese patent medicine market has continued to slow down
.
According to data from Mi Nei.
com, in 2019, China's public medical institutions' terminal sales of proprietary Chinese medicines were 283 billion yuan, a negative growth of 1.
7% for the first time
.
Among them, affected by policies such as medical insurance restrictions, key monitoring, and revision of instructions, the overall market for Chinese medicine injections has declined
.

 

　　High-priced and large-volume varieties have also become the focus of mass procurement of proprietary Chinese medicines
.
For example, Xuesaitong and Xueshuantong have appeared in this alliance procurement list, and Qinghai Province has tested the water before
.
In 2018 China's public medical institutions' terminal TCM injection sales rankings, the sales of Xueshuantong for injection (lyophilized) and Xuesaitong for injection (lyophilized) both exceeded 5 billion yuan, ranking first and second respectively on the TOP list
.
In 2019, the sales of Xueshuantong for injection (lyophilized) reached 6.
283 billion yuan, and Xuesaitong for injection (lyophilized) fell to 3.
928 billion yuan
.

 

　　In addition, Shenmai injection and Shengmai injection have also attracted market attention due to their recommendation in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Seventh Edition)"
.
In the terminal market of China's public medical institutions in 2018, the annual sales of these two varieties exceeded 1 billion yuan, and Shenmai injection exceeded 3 billion yuan
.
However, sales of both varieties declined in 2019, with Shenmai injection sales of 2.
673 billion yuan and Shengmai injection sales of 973 million yuan
.

 

　　While the TCM injection market has declined, some TCM oral medicine markets have performed well
.
In 2020, Jinshuibao film will grow against the trend
.
According to data from Mi Nei.
com, Jinshuibao tablets are the exclusive product of Jiangxi Jimin Trusted Pharmaceutical
.
In recent years, the sales of Jinshuibao tablets in public hospitals in key cities have grown rapidly, from less than 50 million yuan in 2017 to nearly 400 million yuan in 2019
.

 

　　Or from local exploration to national spread

 

　　The national level has repeatedly stated that it will include proprietary Chinese medicines in centralized procurement
.
A few days ago, the National Medical Insurance Administration made it clear in its response to the recommendation No.
4126 of the Fourth Session of the 13th National People’s Congress: The next step will be to work with relevant departments to improve the quality evaluation standards of proprietary Chinese medicines and formula granules, and insist on quality first, and based on clinical needs.
As a guide, starting with high-priced and large-volume varieties, scientifically and steadily promote the reform of centralized procurement of proprietary Chinese medicines and formula granules
.

 

　　Previously, Qinghai Province, Zhejiang Jinhua, Puyang, Henan and other places have a large demand for the part, to the high amount of drugs carried out to explore the kinds of Jicai, achieved positive results
.
The first batch of drug purchase lists issued by Qinghai Province includes Xuesaitong, Xueshuantong, Danshen polyphenolate for injection, Tanreqing, and Xiyanping traditional Chinese medicine injections
.
The second batch of drug purchases carried out by Jinhua City, Zhejiang Province, involving 274 varieties and a total of 180 Chinese patent medicines, including Pudilan Anti-inflammatory Oral Liquid, Yunnan Baiyao Aerosol and Capsules, Shenmai Injection, Xiao'er Soy Bean Granules, etc.

.
Finally, selected product 93, accounting for over 40% of the type of medicine, medicine is 39, including injection, Danshen tablets, pills Liuweidihuang, Qingkailing particles
.

 

　　Since the beginning of this year, procurement of Chinese patent medicines has also been accelerated
.
In April this year, Guangdong took the lead in the centralized procurement of drugs from the 16-province alliance involving dozens of proprietary Chinese medicines
.
Recently, the Sichuan Provincial Bureau issued health care "health care support Sichuan Province medicine development a number of policy" clearly to the provincial inter-provincial or regional alliances, based on the amount of purchases carried out with medicine, Chinese medicine to promote the production companies of high-quality development
.

 

　　Regarding the issue of the inclusion of Chinese patent medicines in centralized procurement, the National Medical Insurance Bureau has stated that it will guide and promote local governments to conduct research on centralized procurement of Chinese patent medicines and other medicines
.
Some people in the industry believe that local special pilot projects may be initiated in 2021, and the country will further develop centralized procurement of proprietary Chinese medicines on this basis when the time is ripe
.

 

　　From the perspective of the industry, although proprietary Chinese medicines have their particularities compared with chemical medicines, especially for the exclusive varieties of Chinese medicines, because there is no competition, there is a lack of motivation to reduce prices
.
In this regard, the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Drug Centralized and Volume Procurement" clearly proposes to explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized and volumetric procurement
.
This also provides a basic follow for the centralized procurement of Chinese patent medicines
.

 

　　The industry believes that the fully competitive or large-volume varieties may be the first to be included, and the market of Chinese patent medicines with a scale of over 300 billion yuan will officially enter the "shuffle" stage with volume purchases
.

 

　　Catalog of varieties of Chinese patent medicines that are purchased in a centralized manner